SK Life Science Held Chicago Plan of Action Meeting

The company gathered over 160 sales staff to strategize on the future commercial growth of cenobamate.

Updated on Oct. 2, 2026 in Remote Work

Isometric editorial illustration of a glass pharmaceutical vial and a geometric molecular structure, representing strategic growth in a medical context. — SK Life Science gathered over 160 sales representatives in Chicago to strategize the commercial growth and market expansion of its medication, cenobamate. AI Illustration. Upload story photo >

Live Poll

Do you trust that pharmaceutical companies prioritize patient health when expanding uses for their existing drugs?

SK Life Science hosted its 2026 Plan of Action meeting in Chicago, bringing together more than 160 sales representatives. The team analyzed performance metrics from the first half of the year to accelerate the market presence of cenobamate.

Why it matters

This strategic gathering focused on synchronizing the efforts of headquarters with the U.S. subsidiary to ensure a unified approach to commercialization. The meeting served as a launchpad for expanding the use of cenobamate across new patient populations.

More than 160 sales staff participated in the meeting to review performance and discuss growth strategies. The firm is currently developing an oral suspension formulation to expand its existing product offerings.

The players

SK Life Science

This pharmaceutical company specializes in the development of treatments for central nervous system disorders.

The details

The company utilized a One Team strategy to unify operational directions while planning for the commercialization of new products. Efforts are specifically targeting the expansion of cenobamate indications to include adolescent and pediatric patients, as well as those with primary generalized tonic-clonic seizures.

The National Sales Meeting was held in February 2026.
The 2026 Plan of Action meeting occurred from September 29 to October 1, 2026.

Market Landscape

This strategic realignment follows the trend of biopharmaceutical companies aggressively seeking to broaden the label of approved medications into new patient categories. By diversifying formulations and populations, SK Life Science aims to strengthen its competitive position in the epilepsy treatment market.

The push to introduce new formulations, such as an oral suspension, could lead to improved accessibility and treatment options for patients who struggle with current medication formats. These corporate strategy shifts reflect the company’s intent to maintain market relevance through expanded pediatric and adolescent care access.

The takeaway

Companies increasingly rely on centralized planning meetings to align national sales teams with shifting therapeutic goals. This internal coordination is essential for successfully navigating the regulatory and commercial pathways required to reach new patient demographics.